Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ (2022)

Publication Type: Journal article

Publication year: 2022


Book Volume: 3

Pages Range: 273-284

Journal Issue: 4

DOI: 10.1158/2643-3230.BCD-21-0205


The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.

Involved external institutions

How to cite


Davies, F.E., Pawlyn, C., Usmani, S.Z., San-Miguel, J.F., Einsele, H., Boyle, E.M.,... Morgan, G.J. (2022). Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 3(4), 273-284.


Davies, Faith E., et al. "Perspectives on the Risk-Stratified Treatment of Multiple Myeloma." Blood Cancer Discovery 3.4 (2022): 273-284.

BibTeX: Download